Abstract
ON the basis of encouraging data from two studies in animals,1 , 2 the manufacturer of the antiretroviral nucleoside analogue zidovudine (formerly azido--thymidine [AZT]) has initiated a placebo-controlled trial to assess the chemoprophylactic efficacy of zidovudine after occupational or nosocomial exposure to the human immunodeficiency virus type 1 (HIV-1).3 , 4 It is unlikely, however, that this trial will be completed soon, given the relatively low risk of infection through occupational exposure.4 In anticipation of the results of the study, several programs of zidovudine chemoprophylaxis for health care workers who have been occupationally exposed to HIV-1 have been implemented.4 The aftermath of a tragic . . .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
